Author of

• 20166

  +

  P1.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies (ID 703)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22838

    +

    P1.17-008 - Clinical and Oncological Outcomes on Resected Thymomas over a Decade at the National Cancer Institute at Mexico City (ID 9293)

    09:30 - 09:30  |  Author(s): J. De La Garza
    • Abstract
    • Slides

    Background:
    Despite the fact that Thymic tumors are considered as an orphan disease, they represent the most common adult tumor in the anterior mediastinum. Most of evidence in this neoplasm comes from small, single institution reports. Moreover, the low incidence and a wide spectrum of clinical and morphological characteristics are well-known factors that difficult treatment decisions.
    
    Method:
    Single Institution, retrospective chart review of patients with resected thymoma, from January 2005 to December 2016.
    
    Result:
    We found 25 patients, with complete clinical data available for review, who underwent thymectomy for epithelial thymic neoplasm. There were 14 females (56%) and 11 males (44%), mean age 56.6 years (27 to 82 years). A total of 22 patients underwent up-front surgery and only 3 patients required neo-adjuvant treatment due to advanced disease. Trans-esternal thymectomy was the most common approach with 18 cases (72%), lateral thoracotomy in 4 cases (16%) and VATS in 3 cases (12%). A complete resection was achieved in 92% of patients. Most of cases, 15 (60%) required an extended thymectomy due to their extension, in 7 (28%) a standard thymectomy was performed,1 case (4%) required a maximal thymectomy and in 2 cases (8%) only a biopsy was performed. R0 resection was achieved in 88% (22 cases) and one patient (4%) was reported as R1 and 2 cases were R2 resections (8%). Distribution according to WHO classification was: A 12%, AB 36%, B1 8%, B2 28%, B3 8% and C 8%. Staging according to Masaoka-Koga Classification was: I 28%, IIA 16%, IIB 24%, III 8%, IVA 12% and IVB 8% Median size of thymomas was 82mm (47-140mm). Mean operative time was 194 minutes (88 – 480), mean blood loss was 362 ml (15 – 2000). Chest tube mean duration was 5.4 days, with a mean hospital stay of 6.2 days (3-18) Morbidity was 24%, but none of patients required re-intervention. Only 2 patients die in the 90 days after surgery for an 8% mortality. In 12 patients (48%) adjuvant treatment was required. Median follow-up was 11.03 months (1.8-108.5) and Median OS was 12.4 months. To date, 21 patients (84%) still alive and only 2 relapses were documented.
    
    Conclusion:
    Surgical resection stills the mainstay of treatment for thymomas. Our series comprises mostly large size thymomas requiring extended thymectomy for complete resection. Despite this fact, our perioperative and oncological results and are encouraging
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.